-
Je něco špatně v tomto záznamu ?
Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA
CH. Brahe, LM. Ørnbjerg, L. Jacobsson, MJ. Nissen, EK. Kristianslund, H. Mann, MJ. Santos, JG. Reino, D. Nordström, Z. Rotar, B. Gudbjornsson, F. Onen, C. Codreanu, U. Lindström, B. Möller, TK. Kvien, K. Pavelka, A. Barcelos, C. Sánchez-Piedra,...
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
Free Medical Journals
od 1996 do Před 1 rokem
Open Access Digital Library
od 1996-01-01
Medline Complete (EBSCOhost)
od 1999-01-01 do Před 1 rokem
- MeSH
- antirevmatika terapeutické užití MeSH
- databáze faktografické MeSH
- dospělí MeSH
- inhibitory TNF terapeutické užití MeSH
- lidé středního věku MeSH
- lidé MeSH
- pacientův souhlas se zdravotní péčí * MeSH
- prospektivní studie MeSH
- psoriatická artritida farmakoterapie MeSH
- registrace MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
OBJECTIVE: To investigate TNF inhibitor (TNFi) retention and response rates in European biologic-naïve patients with PsA. METHODS: Prospectively collected data on PsA patients in routine care from 12 European registries were pooled. Heterogeneity in baseline characteristics between registries were explored (analysis of variance and pairwise comparison). Retention rates (Kaplan-Meier), clinical remission [28-joint count DAS (DAS28) <2.6; 28 joint Disease Activity index for Psoriatic Arthritis ⩽4] and ACR criteria for 20% improvement (ACR20)/ACR50/ACR70 were calculated, including LUNDEX adjustment. RESULTS: Overall, 14 261 patients with PsA initiated a first TNFi. Considerable heterogeneity of baseline characteristics between registries was observed. The median 12-month retention rate (95% CI) was 77% (76, 78%), ranging from 68 to 90% across registries. Overall, DAS28/28 joint Disease Activity index for Psoriatic Arthritis remission rates at 6 months were 56%/27% (LUNDEX: 45%/22%). Six-month ACR20/50/70 responses were 53%/38%/22%, respectively. In patients initiating a first TNFi after 2009 with registered fulfilment of ClASsification for Psoriatic ARthritis (CASPAR) criteria (n = 1980) or registered one or more swollen joint at baseline (n = 5803), the retention rates and response rates were similar to those found overall. CONCLUSION: Approximately half of >14 000 patients with PsA who initiated first TNFi treatment in routine care were in DAS28 remission after 6 months, and three-quarters were still on the drug after 1 year. Considerable heterogeneity in baseline characteristics and outcomes across registries was observed. The feasibility of creating a large European database of PsA patients treated in routine care was demonstrated, offering unique opportunities for research with real-world data.
biorx si and the Department of Rheumatology University Medical Centre Ljubljana Slovenia Ljubljana
Center of Rheumatic Diseases University of Medicine and Pharmacy Bucharest Romania
Department of Rheumatology Diakonhjemmet Hospital Oslo Norway
Department of Rheumatology Geneva University Hospital Geneva Switzerland
GISEA registry Rheumatology Unit DETO University of Bari Bari Italy
Inflammation Center Department of Rheumatology Helsinki University Hospital Helsinki Finland
Research Unit Spanish Society of Rheumatology Madrid Spain
ROB FIN Registry Helsinki University and Helsinki University Hospital Helsinki Finland
TURKBIO Registry and Division of Rheumatology School of Medicine Dokuz Eylul University Izmir Turkey
University of Iceland Faculty of Medicine and Landspitali University Hospital Reykjavik Iceland
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20024936
- 003
- CZ-PrNML
- 005
- 20201222153622.0
- 007
- ta
- 008
- 201125s2020 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1093/rheumatology/kez427 $2 doi
- 035 __
- $a (PubMed)31665497
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Brahe, Cecilie Heegaard $u EuroSpA Coordinating Center, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup. DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark.
- 245 10
- $a Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA / $c CH. Brahe, LM. Ørnbjerg, L. Jacobsson, MJ. Nissen, EK. Kristianslund, H. Mann, MJ. Santos, JG. Reino, D. Nordström, Z. Rotar, B. Gudbjornsson, F. Onen, C. Codreanu, U. Lindström, B. Möller, TK. Kvien, K. Pavelka, A. Barcelos, C. Sánchez-Piedra, KK. Eklund, M. Tomšič, TJ. Love, G. Can, R. Ionescu, AG. Loft, IE. van der Horst-Bruinsma, GJ. Macfarlane, F. Iannone, LH. Hyldstrup, NS. Krogh, M. Østergaard, ML. Hetland,
- 520 9_
- $a OBJECTIVE: To investigate TNF inhibitor (TNFi) retention and response rates in European biologic-naïve patients with PsA. METHODS: Prospectively collected data on PsA patients in routine care from 12 European registries were pooled. Heterogeneity in baseline characteristics between registries were explored (analysis of variance and pairwise comparison). Retention rates (Kaplan-Meier), clinical remission [28-joint count DAS (DAS28) <2.6; 28 joint Disease Activity index for Psoriatic Arthritis ⩽4] and ACR criteria for 20% improvement (ACR20)/ACR50/ACR70 were calculated, including LUNDEX adjustment. RESULTS: Overall, 14 261 patients with PsA initiated a first TNFi. Considerable heterogeneity of baseline characteristics between registries was observed. The median 12-month retention rate (95% CI) was 77% (76, 78%), ranging from 68 to 90% across registries. Overall, DAS28/28 joint Disease Activity index for Psoriatic Arthritis remission rates at 6 months were 56%/27% (LUNDEX: 45%/22%). Six-month ACR20/50/70 responses were 53%/38%/22%, respectively. In patients initiating a first TNFi after 2009 with registered fulfilment of ClASsification for Psoriatic ARthritis (CASPAR) criteria (n = 1980) or registered one or more swollen joint at baseline (n = 5803), the retention rates and response rates were similar to those found overall. CONCLUSION: Approximately half of >14 000 patients with PsA who initiated first TNFi treatment in routine care were in DAS28 remission after 6 months, and three-quarters were still on the drug after 1 year. Considerable heterogeneity in baseline characteristics and outcomes across registries was observed. The feasibility of creating a large European database of PsA patients treated in routine care was demonstrated, offering unique opportunities for research with real-world data.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a antirevmatika $x terapeutické užití $7 D018501
- 650 _2
- $a psoriatická artritida $x farmakoterapie $7 D015535
- 650 _2
- $a databáze faktografické $7 D016208
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a pacientův souhlas se zdravotní péčí $7 D010342
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a registrace $7 D012042
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a inhibitory TNF $x terapeutické užití $7 D000079424
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Ørnbjerg, Lykke Midtbøll $u EuroSpA Coordinating Center, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup. DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark.
- 700 1_
- $a Jacobsson, Lennart $u Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
- 700 1_
- $a Nissen, Michael J $u Department of Rheumatology, Geneva University Hospital, Geneva, Switzerland.
- 700 1_
- $a Kristianslund, Eirik Klami $u Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway.
- 700 1_
- $a Mann, Herman $u Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.
- 700 1_
- $a Santos, Maria José $u Reuma.pt registry and Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
- 700 1_
- $a Reino, Juan Gómez $u Research Unit, Spanish Society of Rheumatology, Madrid, Spain.
- 700 1_
- $a Nordström, Dan $u ROB-FIN Registry, Helsinki University and Helsinki University Hospital, Helsinki, Finland.
- 700 1_
- $a Rotar, Ziga $u biorx.si and the Department of Rheumatology, University Medical Centre Ljubljana, Slovenia, Ljubljana.
- 700 1_
- $a Gudbjornsson, Bjorn $u Centre for Rheumatology Research, University Hospital and Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
- 700 1_
- $a Onen, Fatos $u TURKBIO Registry and Division of Rheumatology, School of Medicine Dokuz Eylul University, Izmir, Turkey.
- 700 1_
- $a Codreanu, Catalin $u Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania.
- 700 1_
- $a Lindström, Ulf $u Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
- 700 1_
- $a Möller, Burkhard $u Leitender Arzt der Universitätsklinik für Rheumatologie, Immunologie und Allergologie Inselspital, Bern, Switzerland.
- 700 1_
- $a Kvien, Tore K $u Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway.
- 700 1_
- $a Pavelka, Karel $u Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.
- 700 1_
- $a Barcelos, Anabela $u Rheuma.pt registry, Rheumatology Department-Centro Hospitalar do Baixo Vouga and Ibimed-Institute for Biomedicine, University of Aveiro, Aveiro, Portugal.
- 700 1_
- $a Sánchez-Piedra, Carlos $u Research Unit, Spanish Society of Rheumatology, Madrid, Spain.
- 700 1_
- $a Eklund, Kari K $u Inflammation Center, Department of Rheumatology, Helsinki University Hospital, Helsinki, Finland.
- 700 1_
- $a Tomšič, Matija $u biorx.si and the Department of Rheumatology, University Medical Centre Ljubljana, Slovenia, Ljubljana.
- 700 1_
- $a Love, Thorvardur Jon $u University of Iceland, Faculty of Medicine, and Landspitali University Hospital, Reykjavik, Iceland.
- 700 1_
- $a Can, Gercek $u TURKBIO Registry and Division of Rheumatology, School of Medicine Dokuz Eylul University, Izmir, Turkey.
- 700 1_
- $a Ionescu, Ruxandra $u Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania.
- 700 1_
- $a Loft, Anne Gitte $u DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark. Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark.
- 700 1_
- $a van der Horst-Bruinsma, I E $u Amsterdam Rheumatology & immunology Center (ARC), Academic Medical Center, Amsterdam. Department of Rheumatology, Amsterdam UMC, VU University Medical Centre Amsterdam, Amsterdam, The Netherlands.
- 700 1_
- $a Macfarlane, Gary J $u Epidemiology Group, School of Medicine, Medical Science and Nutrition, University of Aberdeen, Aberdeen, UK.
- 700 1_
- $a Iannone, Florenzo $u GISEA registry, Rheumatology Unit - DETO, University of Bari, Bari, Italy.
- 700 1_
- $a Hyldstrup, Lise Hejl $u EuroSpA Coordinating Center, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup.
- 700 1_
- $a Krogh, Niels Steen $u Zitelabs Aps, Copenhagen.
- 700 1_
- $a Østergaard, Mikkel $u EuroSpA Coordinating Center, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup. Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
- 700 1_
- $a Hetland, Merete Lund $u EuroSpA Coordinating Center, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup. Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
- 773 0_
- $w MED00011379 $t Rheumatology (Oxford, England) $x 1462-0332 $g Roč. 59, č. 7 (2020), s. 1640-1650
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31665497 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201222153618 $b ABA008
- 999 __
- $a ok $b bmc $g 1599081 $s 1115622
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 59 $c 7 $d 1640-1650 $e 20200701 $i 1462-0332 $m Rheumatology $n Rheumatology (Oxford) $x MED00011379
- LZP __
- $a Pubmed-20201125
